At a glance
ClinicalIndex Comparison RecordN/ACompleted· 10 enrolled
Drug / intervention
Rocuronium Bromidedrug
Likely dose
Rocuronium Bromide 0,3 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacokinetic and Pharmacodynamic of Rocuronium Bromide Measured in Adductor Pollicis and Masseter Muscles.
In Brief
An observational study evaluating Rocuronium Bromide for Neuromuscular Blockade. Completed, enrolled 10 participants.
Detailed Summary
The purpose of this study is characterize the dose-effect relationship of rocuronium bromide at the adductor pollicis and masseter muscles using an pharmacokinetic-pharmacodynamic (PKPD) model. The hypothesis is that masseter muscle has a greater sensitivity to the neuromuscular blockers (rocuronium), faster onset and slower recovery profile than the adductor pollicis muscle.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNeuromuscular Blockade
Countries--
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2013
Primary CompletionNov 2013
Study CompletionJan 2015
First PostedMar 2015
TodayJul 2026
First PostedMar 3, 2015
Enrollment StartMar 1, 2013
Primary CompletionNov 1, 2013
Study CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 11.3 years ago
Interventions
Rocuronium Bromidedrug
Rocuronium 0,3 mg/kg in less than five seconds, followed by a saline bolus.